151 related articles for article (PubMed ID: 30782378)
1. Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
Ferrara R; Caramella C; Besse B; Champiat S
J Thorac Oncol; 2019 Mar; 14(3):328-331. PubMed ID: 30782378
[No Abstract] [Full Text] [Related]
2. Clinical Experience of Immunotherapy Treatment: Efficacy and Toxicity Analysis of the Compassionate Use Program of Nivolumab in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer.
Krefting F; Basara N; Schütte W; Späth-Schwalbe E; Alt J; Thiel S; Kimmich M; Fischer JR; Kurz S; Griesinger F; Christoph DC
Oncol Res Treat; 2019; 42(5):243-255. PubMed ID: 30995666
[TBL] [Abstract][Full Text] [Related]
3. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
4. Well-controlled pleural effusion indicated pseudoprogression after immunotherapy in lung cancer: A case report.
Liu G; Chen T; Li R; Zhu L; Liu D; Ding Z
Thorac Cancer; 2018 Sep; 9(9):1190-1193. PubMed ID: 29978949
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccination in patients with lung cancer receiving anti-programmed death receptor 1 immunotherapy does not induce immune-related adverse events.
Wijn DH; Groeneveld GH; Vollaard AM; Muller M; Wallinga J; Gelderblom H; Smit EF
Eur J Cancer; 2018 Nov; 104():182-187. PubMed ID: 30368069
[TBL] [Abstract][Full Text] [Related]
6. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
[TBL] [Abstract][Full Text] [Related]
7. Commentary: Cautious optimism for induction immunotherapy in resectable lung cancer.
Lanuti M
J Thorac Cardiovasc Surg; 2019 Jul; 158(1):277-278. PubMed ID: 31103202
[No Abstract] [Full Text] [Related]
8. Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab.
Johnson DY; Short RG; Patz EF
Clin Lung Cancer; 2018 Mar; 19(2):175-180. PubMed ID: 29153896
[TBL] [Abstract][Full Text] [Related]
9. Understanding immunotherapy for the treatment of non-small cell lung cancer.
Thomas R
Br J Nurs; 2016 Sep; 25(16):S12-7. PubMed ID: 27615536
[TBL] [Abstract][Full Text] [Related]
10. [Nivolumab, a new hope in non-small cell lung cancer].
Flippot R; Fallet V; Besse B; Massard C; Wislez M; Vignot S
Bull Cancer; 2015 Dec; 102(12):1046-52. PubMed ID: 26585939
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Garassino MC; Crinò L; Catino A; Ardizzoni A; Cortesi E; Cappuzzo F; Bordi P; Calabrò L; Barbieri F; Santo A; Altavilla G; Ambrosio F; Mini E; Vasile E; Morgillo F; Scoppola A; Bengala C; Follador A; Tedde N; Giannarelli D; Lo Russo G; Vitiello F
Tumour Biol; 2018 Nov; 40(11):1010428318815047. PubMed ID: 30486741
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
Waqar SN; Morgensztern D
Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-edged Sword.
Tang C; Jiang W; Yap TA
JAMA Oncol; 2018 Aug; 4(8):1116-1117. PubMed ID: 29327039
[No Abstract] [Full Text] [Related]
14. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.
Yoshida T; Furuta H; Hida T
Med Oncol; 2017 Mar; 34(3):34. PubMed ID: 28138869
[TBL] [Abstract][Full Text] [Related]
15. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
[TBL] [Abstract][Full Text] [Related]
16. High TMB Predicts Immunotherapy Benefit.
Cancer Discov; 2018 Jun; 8(6):668. PubMed ID: 29661758
[TBL] [Abstract][Full Text] [Related]
17. [Nivolumab and sarcoid reaction in lung cancer treatment].
Vergnon JM; Tissot CL
Rev Mal Respir; 2019 Feb; 36(2):230-232. PubMed ID: 30745234
[No Abstract] [Full Text] [Related]
18. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals.
Tournoy KG; Thomeer M; Germonpré P; Derijcke S; De Pauw R; Galdermans D; Govaert K; Govaerts E; Schildermans R; Declercq I; De Brucker N; Pat K; Van Herreweghe R; Van Zandweghe L; Vanmaele L; Van Damme V; Marien H; De Craene S; Fabry I; Alexander P; Vercauter P; Demedts I
Lung Cancer; 2018 Jan; 115():49-55. PubMed ID: 29290261
[TBL] [Abstract][Full Text] [Related]
19. Report of two cases of pseudoprogression in patients with non-small cell lung cancer treated with nivolumab-including histological analysis of one case after tumor regression.
Tanizaki J; Hayashi H; Kimura M; Tanaka K; Takeda M; Shimizu S; Ito A; Nakagawa K
Lung Cancer; 2016 Dec; 102():44-48. PubMed ID: 27987588
[TBL] [Abstract][Full Text] [Related]
20. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
